Incidence of Co-infection and its Impact on COVID-19 Patients admitted in the Intensive Care Unit
Viral-bacterial co-infections are one of the most serious medical issues, with higher fatality rates. Few investigations have studied bacterial superinfections in individuals with coronavirus disease 2019 (COVID-19). Hence, we carried out the current research to assess the different types of seconda...
Gespeichert in:
| Veröffentlicht in: | Egyptian journal of anaesthesia 2023-12, Vol.39 (1), p.141-148 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 148 |
|---|---|
| container_issue | 1 |
| container_start_page | 141 |
| container_title | Egyptian journal of anaesthesia |
| container_volume | 39 |
| creator | Touny, Aiman Rageh, Fatma Riad, Eman Sakr, Mohamed A. Abdelhady, Shaymaa Abdelraheem Elgamal, Rasha Ahmed, Samar S. Al-Touny, Shimaa A. |
| description | Viral-bacterial co-infections are one of the most serious medical issues, with higher fatality rates. Few investigations have studied bacterial superinfections in individuals with coronavirus disease 2019 (COVID-19). Hence, we carried out the current research to assess the different types of secondary bacterial and fungal infections and their response to antibiotics and antifungals that affect COVID-19 patients' outcomes when admitted to the intensive care unit (ICU).
A total of 65 COVID-19 patients admitted to the ICU were studied in this cross-sectional study. Endotracheal aspirate or sputum samples and blood samples were collected using strict infection control procedures. The bacterial isolates were identified using gram staining, growth characteristics, and standard biochemical reactions with antimicrobial susceptibility testing. Fungal infections were determined by serological assays.
The incidence of bacterial co-infection was 47.7%. Death was significantly higher among COVID-19 patients with secondary infection (P |
| doi_str_mv | 10.1080/11101849.2023.2175404 |
| format | Article |
| fullrecord | <record><control><sourceid>doaj_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_11101849_2023_2175404</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_35e3d5db427844a497ec226d6fafbb1b</doaj_id><sourcerecordid>oai_doaj_org_article_35e3d5db427844a497ec226d6fafbb1b</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-56758ca005d91d53d2a152b6b63c135b1f684b361b554586551aadf53fe520463</originalsourceid><addsrcrecordid>eNp9kMtqHTEMhofSQEKaRwj4BebUsi3PzK5lehsIpIumWyPfUodz7OAxLXn7zslJS1fVRuKX9C2-rrsGvgM-8rcAwGFU005wIXcCBlRcveoujnl_XLz-Zz7vrtb1gW-lOeppvOhoyS75kF1gJbK59CnH4FoqmVH2LLWVLYdHco1tyXz7ffnQw8S-Ukshbzvyh9Ra2A4zaz8CW3ILeU0_A5upBnaXU3vTnUXar-HqpV92d58-fpu_9De3n5f5_U3v5ACtRz3g6Ihz9BN4lF4QoLDaaulAooWoR2WlBouocNSIQOQjyhhQcKXlZbecuL7Qg3ms6UD1yRRK5jko9d5Qbcntg5EYpEdvlRhGpUhNQ3BCaK8jRWvBbiw8sVwt61pD_MsDbo7azR_t5qjdvGjf_t6d_jaLpR7oV6l7bxo97UuNlTbVq5H_R_wGQTWGrQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Incidence of Co-infection and its Impact on COVID-19 Patients admitted in the Intensive Care Unit</title><source>Taylor & Francis Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Touny, Aiman ; Rageh, Fatma ; Riad, Eman ; Sakr, Mohamed A. ; Abdelhady, Shaymaa Abdelraheem ; Elgamal, Rasha ; Ahmed, Samar S. ; Al-Touny, Shimaa A.</creator><creatorcontrib>Touny, Aiman ; Rageh, Fatma ; Riad, Eman ; Sakr, Mohamed A. ; Abdelhady, Shaymaa Abdelraheem ; Elgamal, Rasha ; Ahmed, Samar S. ; Al-Touny, Shimaa A.</creatorcontrib><description>Viral-bacterial co-infections are one of the most serious medical issues, with higher fatality rates. Few investigations have studied bacterial superinfections in individuals with coronavirus disease 2019 (COVID-19). Hence, we carried out the current research to assess the different types of secondary bacterial and fungal infections and their response to antibiotics and antifungals that affect COVID-19 patients' outcomes when admitted to the intensive care unit (ICU).
A total of 65 COVID-19 patients admitted to the ICU were studied in this cross-sectional study. Endotracheal aspirate or sputum samples and blood samples were collected using strict infection control procedures. The bacterial isolates were identified using gram staining, growth characteristics, and standard biochemical reactions with antimicrobial susceptibility testing. Fungal infections were determined by serological assays.
The incidence of bacterial co-infection was 47.7%. Death was significantly higher among COVID-19 patients with secondary infection (P < 0.001). The clinical isolates were 34, of which 31 (91.18%) were bacteria and 3 (8.82%) were fungi. Klebsiella pneumonia and Acinetobacter baumannii were the predominant gram-negative bacteria; representing 38% and 17.65%, respectively. Staphylococcus aureus was the predominant isolated gram-positive bacteria represented 11.76%. Candida albicans were the predominantly isolated fungi. Tigecycline and amikacin were the most sensitive antibiotics for associated bacterial co-infection of COVID-19 cases (80.6% and 70.9%, respectively). Flucytosine, amphotericin B, caspofungin, and micafungin were all found to be sensitive against candida Albicans isolates.
Mortality was significantly higher among COVID-19 patients with secondary bacterial and fungal co-infection. Klebsiella pneumonia and Acinetobacter baumannii were the most common co-infecting agents. Tigecycline and amikacin displayed the highest sensitivity patterns.</description><identifier>ISSN: 1110-1849</identifier><identifier>EISSN: 1110-1849</identifier><identifier>DOI: 10.1080/11101849.2023.2175404</identifier><language>eng</language><publisher>Taylor & Francis</publisher><subject>antibiotic ; co-infection ; COVID-19 ; ICU</subject><ispartof>Egyptian journal of anaesthesia, 2023-12, Vol.39 (1), p.141-148</ispartof><rights>2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c371t-56758ca005d91d53d2a152b6b63c135b1f684b361b554586551aadf53fe520463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/11101849.2023.2175404$$EPDF$$P50$$Ginformaworld$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/11101849.2023.2175404$$EHTML$$P50$$Ginformaworld$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,860,2096,27479,27901,27902,59116,59117</link.rule.ids></links><search><creatorcontrib>Touny, Aiman</creatorcontrib><creatorcontrib>Rageh, Fatma</creatorcontrib><creatorcontrib>Riad, Eman</creatorcontrib><creatorcontrib>Sakr, Mohamed A.</creatorcontrib><creatorcontrib>Abdelhady, Shaymaa Abdelraheem</creatorcontrib><creatorcontrib>Elgamal, Rasha</creatorcontrib><creatorcontrib>Ahmed, Samar S.</creatorcontrib><creatorcontrib>Al-Touny, Shimaa A.</creatorcontrib><title>Incidence of Co-infection and its Impact on COVID-19 Patients admitted in the Intensive Care Unit</title><title>Egyptian journal of anaesthesia</title><description>Viral-bacterial co-infections are one of the most serious medical issues, with higher fatality rates. Few investigations have studied bacterial superinfections in individuals with coronavirus disease 2019 (COVID-19). Hence, we carried out the current research to assess the different types of secondary bacterial and fungal infections and their response to antibiotics and antifungals that affect COVID-19 patients' outcomes when admitted to the intensive care unit (ICU).
A total of 65 COVID-19 patients admitted to the ICU were studied in this cross-sectional study. Endotracheal aspirate or sputum samples and blood samples were collected using strict infection control procedures. The bacterial isolates were identified using gram staining, growth characteristics, and standard biochemical reactions with antimicrobial susceptibility testing. Fungal infections were determined by serological assays.
The incidence of bacterial co-infection was 47.7%. Death was significantly higher among COVID-19 patients with secondary infection (P < 0.001). The clinical isolates were 34, of which 31 (91.18%) were bacteria and 3 (8.82%) were fungi. Klebsiella pneumonia and Acinetobacter baumannii were the predominant gram-negative bacteria; representing 38% and 17.65%, respectively. Staphylococcus aureus was the predominant isolated gram-positive bacteria represented 11.76%. Candida albicans were the predominantly isolated fungi. Tigecycline and amikacin were the most sensitive antibiotics for associated bacterial co-infection of COVID-19 cases (80.6% and 70.9%, respectively). Flucytosine, amphotericin B, caspofungin, and micafungin were all found to be sensitive against candida Albicans isolates.
Mortality was significantly higher among COVID-19 patients with secondary bacterial and fungal co-infection. Klebsiella pneumonia and Acinetobacter baumannii were the most common co-infecting agents. Tigecycline and amikacin displayed the highest sensitivity patterns.</description><subject>antibiotic</subject><subject>co-infection</subject><subject>COVID-19</subject><subject>ICU</subject><issn>1110-1849</issn><issn>1110-1849</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>DOA</sourceid><recordid>eNp9kMtqHTEMhofSQEKaRwj4BebUsi3PzK5lehsIpIumWyPfUodz7OAxLXn7zslJS1fVRuKX9C2-rrsGvgM-8rcAwGFU005wIXcCBlRcveoujnl_XLz-Zz7vrtb1gW-lOeppvOhoyS75kF1gJbK59CnH4FoqmVH2LLWVLYdHco1tyXz7ffnQw8S-Ukshbzvyh9Ra2A4zaz8CW3ILeU0_A5upBnaXU3vTnUXar-HqpV92d58-fpu_9De3n5f5_U3v5ACtRz3g6Ihz9BN4lF4QoLDaaulAooWoR2WlBouocNSIQOQjyhhQcKXlZbecuL7Qg3ms6UD1yRRK5jko9d5Qbcntg5EYpEdvlRhGpUhNQ3BCaK8jRWvBbiw8sVwt61pD_MsDbo7azR_t5qjdvGjf_t6d_jaLpR7oV6l7bxo97UuNlTbVq5H_R_wGQTWGrQ</recordid><startdate>20231231</startdate><enddate>20231231</enddate><creator>Touny, Aiman</creator><creator>Rageh, Fatma</creator><creator>Riad, Eman</creator><creator>Sakr, Mohamed A.</creator><creator>Abdelhady, Shaymaa Abdelraheem</creator><creator>Elgamal, Rasha</creator><creator>Ahmed, Samar S.</creator><creator>Al-Touny, Shimaa A.</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>DOA</scope></search><sort><creationdate>20231231</creationdate><title>Incidence of Co-infection and its Impact on COVID-19 Patients admitted in the Intensive Care Unit</title><author>Touny, Aiman ; Rageh, Fatma ; Riad, Eman ; Sakr, Mohamed A. ; Abdelhady, Shaymaa Abdelraheem ; Elgamal, Rasha ; Ahmed, Samar S. ; Al-Touny, Shimaa A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-56758ca005d91d53d2a152b6b63c135b1f684b361b554586551aadf53fe520463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>antibiotic</topic><topic>co-infection</topic><topic>COVID-19</topic><topic>ICU</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Touny, Aiman</creatorcontrib><creatorcontrib>Rageh, Fatma</creatorcontrib><creatorcontrib>Riad, Eman</creatorcontrib><creatorcontrib>Sakr, Mohamed A.</creatorcontrib><creatorcontrib>Abdelhady, Shaymaa Abdelraheem</creatorcontrib><creatorcontrib>Elgamal, Rasha</creatorcontrib><creatorcontrib>Ahmed, Samar S.</creatorcontrib><creatorcontrib>Al-Touny, Shimaa A.</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>CrossRef</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Egyptian journal of anaesthesia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Touny, Aiman</au><au>Rageh, Fatma</au><au>Riad, Eman</au><au>Sakr, Mohamed A.</au><au>Abdelhady, Shaymaa Abdelraheem</au><au>Elgamal, Rasha</au><au>Ahmed, Samar S.</au><au>Al-Touny, Shimaa A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incidence of Co-infection and its Impact on COVID-19 Patients admitted in the Intensive Care Unit</atitle><jtitle>Egyptian journal of anaesthesia</jtitle><date>2023-12-31</date><risdate>2023</risdate><volume>39</volume><issue>1</issue><spage>141</spage><epage>148</epage><pages>141-148</pages><issn>1110-1849</issn><eissn>1110-1849</eissn><abstract>Viral-bacterial co-infections are one of the most serious medical issues, with higher fatality rates. Few investigations have studied bacterial superinfections in individuals with coronavirus disease 2019 (COVID-19). Hence, we carried out the current research to assess the different types of secondary bacterial and fungal infections and their response to antibiotics and antifungals that affect COVID-19 patients' outcomes when admitted to the intensive care unit (ICU).
A total of 65 COVID-19 patients admitted to the ICU were studied in this cross-sectional study. Endotracheal aspirate or sputum samples and blood samples were collected using strict infection control procedures. The bacterial isolates were identified using gram staining, growth characteristics, and standard biochemical reactions with antimicrobial susceptibility testing. Fungal infections were determined by serological assays.
The incidence of bacterial co-infection was 47.7%. Death was significantly higher among COVID-19 patients with secondary infection (P < 0.001). The clinical isolates were 34, of which 31 (91.18%) were bacteria and 3 (8.82%) were fungi. Klebsiella pneumonia and Acinetobacter baumannii were the predominant gram-negative bacteria; representing 38% and 17.65%, respectively. Staphylococcus aureus was the predominant isolated gram-positive bacteria represented 11.76%. Candida albicans were the predominantly isolated fungi. Tigecycline and amikacin were the most sensitive antibiotics for associated bacterial co-infection of COVID-19 cases (80.6% and 70.9%, respectively). Flucytosine, amphotericin B, caspofungin, and micafungin were all found to be sensitive against candida Albicans isolates.
Mortality was significantly higher among COVID-19 patients with secondary bacterial and fungal co-infection. Klebsiella pneumonia and Acinetobacter baumannii were the most common co-infecting agents. Tigecycline and amikacin displayed the highest sensitivity patterns.</abstract><pub>Taylor & Francis</pub><doi>10.1080/11101849.2023.2175404</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1110-1849 |
| ispartof | Egyptian journal of anaesthesia, 2023-12, Vol.39 (1), p.141-148 |
| issn | 1110-1849 1110-1849 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_11101849_2023_2175404 |
| source | Taylor & Francis Open Access; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | antibiotic co-infection COVID-19 ICU |
| title | Incidence of Co-infection and its Impact on COVID-19 Patients admitted in the Intensive Care Unit |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T00%3A21%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-doaj_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incidence%20of%20Co-infection%20and%20its%20Impact%20on%20COVID-19%20Patients%20admitted%20in%20the%20Intensive%20Care%20Unit&rft.jtitle=Egyptian%20journal%20of%20anaesthesia&rft.au=Touny,%20Aiman&rft.date=2023-12-31&rft.volume=39&rft.issue=1&rft.spage=141&rft.epage=148&rft.pages=141-148&rft.issn=1110-1849&rft.eissn=1110-1849&rft_id=info:doi/10.1080/11101849.2023.2175404&rft_dat=%3Cdoaj_cross%3Eoai_doaj_org_article_35e3d5db427844a497ec226d6fafbb1b%3C/doaj_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_doaj_id=oai_doaj_org_article_35e3d5db427844a497ec226d6fafbb1b&rfr_iscdi=true |